The INSPIRE Comparative Cost Study: 12-Month Health Economic and Clinical Outcomes Associated with Hysterectomy, Myomectomy, and Treatment with the Sonata System

• Published in: ClinicoEconomics and outcomes research 2020-01, Vol.12, p.1-11
• Main Authors: Brooks, Elizabeth, Mihalov, Linda, Delvadia, Dipak, Hudgens, Joseph, Mama, Saifuddin, Makai, Gretchen E, Yuen, Matt W, Little, Carter A, Bauserman, Robert L, Zambelli-Weiner, April, Levine, David J
• Format: Article
• Language: English
• Subjects: Ablation (Surgery); Clinical trials; Comparative analysis; Economic aspects; Health care costs; health care resource utilization; Hysterectomy; Leiomyoma; Medical care utilization; Medical economics; Original Research; payer perspective analysis; Prescriptions (Drugs); Prospective payment systems (Medical care); Radiology; tfa; Time; transcervical fibroid ablation; Ultrasound imaging; Uterine fibroids; uterine preserving treatment; Women's health
• ISSN: 1178-6981; 1178-6981
• DOI: 10.2147/CEOR.S214755

The INSPIRE study compared perioperative and 12-month health economic and clinical outcomes associated with hysterectomy, myomectomy, and sonography-guided transcervical fibroid ablation (TFA) using the Sonata system. Cost and health care resource utilization (HCRU) data for TFA were obtained from a prospective, multicenter, single-arm clinical trial. Data for hysterectomy and myomectomy arms were derived from the Truven Health MarketScan commercial payer claims database. The Truven data was used to determine health economic outcomes and costs for the hysterectomy and myomectomy arms. For each arm, payer perspective costs were estimated from the available charge and HCRU data. TFA with Sonata had significantly lower mean length of stay (LOS) of 5 hrs versus hysterectomy (73 hrs) or myomectomy (79 hrs; all < 0.001). The average payer cost for TFA treatment, including the associated postoperative HCRU was $8,941. This was significantly lower compared to hysterectomy ($24,156) and myomectomy ($22,784; all < 0.001). In the TFA arm, there were no device- or procedure-related costs associated with complications during the peri- or postoperative time frame. TFA subjects had significantly lower costs associated with complications, prescription medications, and radiology. Compared to hysterectomy and myomectomy, TFA treatment with the Sonata system was associated with significantly lower index procedure cost, complication cost, and LOS, contributing to a lower total payer cost through 12 months.